Research Guide

CJC-1295 and Ipamorelin: A Researcher's Guide to GHRH and GHRP Combination Studies

Key Takeaways At a Glance
  • ✓CJC-1295 (with DAC) is a GHRH analogue with albumin-binding modification extending plasma half-life to ~6-8 days, enabling sustained GHRH receptor stimulation
  • ✓Ipamorelin is a selective GHSR1a agonist with significantly lower cortisol/ACTH activity than earlier GHRPs (GHRP-2, GHRP-6) — making it the preferred GHRP in contemporary research
  • ✓Combined, they act synergistically: CJC-1295 amplifies GH pulse magnitude, ipamorelin increases pulse frequency — producing greater total GH output than either alone
  • ✓A Phase 2 clinical trial (Teichman et al., J Clin Endocrinol Metab, 2006) documented sustained GH/IGF-1 elevation lasting 6 days post-single CJC-1295 administration
  • ✓Available as a 5mg/5mg co-lyophilised blend from Eternal Peptides Wholesale — Janoshik-verified, for qualified laboratory research use only

In This Article

  1. CJC-1295: GHRH Receptor Pharmacology
  2. Ipamorelin: Selective GHRP
  3. Synergistic Combination Rationale
  4. Published Clinical Data
  5. Comparison with Other GHRPs
  6. Available for Research
  7. FAQ

CJC-1295 and Ipamorelin work through different receptor populations on the same target cells — and that mechanistic distinction is precisely why they're studied together. This guide covers the receptor pharmacology of each compound, the published human evidence for CJC-1295 (Teichman 2006), Ipamorelin's selectivity profile, and the rationale for combination protocols in GH secretion research. For research purposes only. Not for human therapeutic use.

Published: April 2026·~1,300 words·6 min read
Free shipping on all products.
Research Use Disclaimer: All information is derived from published peer-reviewed literature. CJC-1295 and Ipamorelin are not approved by the TGA for therapeutic use in Australia. Products sold by Eternal Peptides Wholesale are for qualified laboratory research use only — not for human therapeutic use or consumption.

GH Secretion Physiology: GHRHR and GHSR Pathways

Growth hormone secretion from anterior pituitary somatotrophs is regulated by two primary inputs from the hypothalamus: growth hormone releasing hormone (GHRH), which stimulates GH release, and somatostatin (SST), which inhibits it. A third pathway — the ghrelin/GHSR axis — operates semi-independently, stimulating GH secretion through a receptor population that is distinct from the GHRH receptor (GHRHR) but present on the same somatotroph cells.

CJC-1295 acts at the GHRHR. Ipamorelin acts at the GHSR. This means the two compounds activate the same output (GH release from somatotrophs) through entirely different receptor-ligand interactions. Stimulating both simultaneously results in additive signalling — both pathways drive GH secretion, and neither saturates the other. This is the mechanistic basis for the synergy observed when the two compounds are combined in research protocols.

Understanding this dual-receptor architecture is essential context for interpreting combination study results. When you see a GH secretion response from a CJC-1295 + Ipamorelin protocol, you cannot attribute it solely to GHRHR activation or solely to GHSR activation — it's the product of both pathways operating simultaneously.

CJC-1295: Long-Acting GHRH with the DAC Modification

Native GHRH has a plasma half-life of 6–7 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase. This makes it pharmacologically impractical for research protocols requiring sustained GHRH stimulation. CJC-1295 addresses this through the Drug Affinity Complex (DAC) modification — a reactive maleimide group that forms a covalent bond with cysteine-34 on circulating serum albumin after injection, effectively piggybacking on albumin's 19-day half-life.

The result is a GHRH analogue with a plasma half-life of approximately 6–8 days, enabling sustained GHRHR stimulation from a single administration. This is a fundamentally different pharmacokinetic profile from native GHRH or shorter-acting analogues — and it's what makes CJC-1295 distinctively useful in research contexts where prolonged, stable GH axis stimulation is the experimental goal.

Teichman 2006: The Published Human Evidence

The 2006 study by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism is the foundational published reference for CJC-1295's human pharmacokinetics. The randomised, double-blind, placebo-controlled study in 66 healthy adults assessed GH and IGF-1 responses to a single subcutaneous injection across four dose cohorts (30, 60, 120, and 240 µg/kg).

Key findings: mean 24-hour GH concentrations increased 2–10 fold above baseline in a dose-dependent manner; serum IGF-1 levels increased 1.5–3 fold; and both GH and IGF-1 elevations persisted for up to 28 days following a single injection — consistent with the DAC-mediated half-life extension. The pharmacokinetic profile was distinct from anything seen with native GHRH or other short-acting analogues, confirming the DAC mechanism's biological effect in humans.

This study remains the primary human reference point for CJC-1295. It's a Phase 1/2 pharmacokinetics study in healthy volunteers — not a therapeutic outcomes trial — which is an important distinction for how its data should be interpreted in a research context.

Ipamorelin: Selective GHSR Agonism

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a synthetic pentapeptide ghrelin mimetic developed in the late 1990s. Its receptor target — the GHSR (growth hormone secretagogue receptor) — is the same receptor activated by ghrelin, the endogenous "hunger hormone." GHSR activation on pituitary somatotrophs stimulates GH secretion through a Gq/phospholipase C mechanism, distinct from the GHRHR's Gs/adenylate cyclase pathway used by GHRH and CJC-1295.

What distinguishes Ipamorelin from earlier GH secretagogues like GHRP-2 and GHRP-6 is its selectivity. Raun et al. (1998) in the European Journal of Endocrinology — the foundational publication on Ipamorelin — demonstrated that in rats, Ipamorelin produced robust, dose-dependent GH release at comparable or greater magnitude than GHRP-6, but without the statistically significant cortisol, ACTH, or prolactin elevations seen with GHRP-6 at equivalent doses. This selectivity profile is not unique to the rat model; subsequent pharmacokinetic studies confirmed a similar selectivity in other species.

The practical implication for research: if your experimental protocol needs GH secretion to be the isolatable variable — and you don't want concurrent HPA axis activation to complicate your readouts — Ipamorelin is the GHSR agonist of choice. GHRP-2 and GHRP-6 both reliably activate cortisol and ACTH release, which confounds GH-specific analyses in contexts where stress axis interference matters.

Combination Research Rationale: Why GHRHR + GHSR

The rationale for combining CJC-1295 and Ipamorelin is mechanistically straightforward. GH release from somatotrophs is potentiated when both GHRHR and GHSR are activated simultaneously — the two pathways converge on calcium mobilisation and GH vesicle exocytosis through different second messenger systems, and their combined activation produces a larger GH pulse than either pathway alone.

In a research design context, combining both compounds allows investigators to study the full GHRH/ghrelin axis simultaneously, to compare combined-receptor versus single-receptor GH secretion profiles, or to achieve specific GH pulse amplitudes for downstream endpoint analyses (IGF-1, IGFBP-3, growth rate in animal models) that may not be achievable with either compound alone at tolerated doses.

Sermorelin — a shorter-acting GHRH analogue — is sometimes considered alongside CJC-1295 in combination protocols where a more physiological GH pulse pattern (sharper peak, faster clearance) is preferred over CJC-1295's sustained elevation. The choice between CJC-1295 and Sermorelin as the GHRHR component depends on the pharmacokinetic profile required by the specific research protocol.

GH Axis Research Peptides — Janoshik Verified
HPLC purity ≥98% · Mass spec confirmed · Sterility & endotoxin tested · COA on every batch
CJC-1295 10mg (CP10) Ipamorelin 10mg (IP10) Sermorelin 5mg (SMO5) Sermorelin 10mg (SMO10)
EP
Eternal Peptides Research Team
Published April 2026 · Updated April 2026 · For research use only

Frequently Asked Questions

What is CJC-1295?
CJC-1295 is a synthetic GHRH analogue with a DAC (Drug Affinity Complex) modification that enables albumin binding and extends plasma half-life to ~6–8 days. It stimulates GH release from pituitary somatotrophs via the GHRH receptor. Teichman et al. (2006, JCEM) demonstrated dose-dependent GH and IGF-1 elevations persisting for 28 days following a single injection in healthy adults. For research use only.
Why is Ipamorelin preferred over GHRP-2 or GHRP-6 in research?
Ipamorelin's selectivity profile. GHRP-2 and GHRP-6 produce GH release but simultaneously stimulate significant cortisol and ACTH secretion, which confounds research trying to isolate GH pathway effects. Ipamorelin achieves comparable GH stimulation via GHSR without the HPA axis activation, giving researchers a cleaner signal when studying GH-specific outcomes. Raun et al. (1998) documented this selectivity difference formally.
What did Teichman 2006 find about CJC-1295 in humans?
The Phase 2 RCT in 66 healthy adults documented dose-dependent GH increases (2–10× baseline), serum IGF-1 increases (1.5–3×), and persistence of both elevations for up to 28 days following a single injection. These findings confirmed the pharmacological effectiveness of the DAC modification in extending CJC-1295's activity in human subjects. The study was a pharmacokinetics study, not a therapeutic outcomes trial.
What is the difference between CJC-1295 and Sermorelin?
Both are GHRH analogues acting at the GHRHR. Sermorelin is the first 29 amino acids of native GHRH — the biologically active fragment — without modification. It has a short half-life (~20–30 min) producing GH pulses closer to physiological patterns. CJC-1295 has the DAC modification extending its half-life to 6–8 days, producing sustained GH elevation. The choice between them depends on whether your research protocol requires pulsatile physiological GH dynamics (Sermorelin) or stable sustained stimulation (CJC-1295 with DAC).
Are these approved for therapeutic use in Australia?
No. CJC-1295 and Ipamorelin in their research peptide forms are not TGA-registered for therapeutic use in Australia. All products from Eternal Peptides Wholesale are supplied for qualified laboratory research purposes only. Sermorelin has regulatory history in other jurisdictions but is similarly supplied here for research use only.

Key References

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
  3. Ghigo E, et al. Spontaneous growth hormone secretion in man: the effects of GHRH and GHS. Growth Horm IGF Res. 2001;11 Suppl A:S127-S133.
  4. Popovic V, et al. Growth hormone secretion in obesity. J Pediatr Endocrinol Metab. 2001;14 Suppl 5:1273-1281.
  5. Veldhuis JD, et al. Mechanisms and consequences of amplified growth hormone secretion. Pediatr Endocrinol Rev. 2012;9(4):789-805.
Important: This article summarises published research for informational purposes only. CJC-1295 and Ipamorelin are not TGA-approved for therapeutic use in Australia. Nothing here constitutes medical advice or a clinical protocol. All products are for qualified laboratory research purposes only and are not for human therapeutic use or consumption.